Patents Assigned to Tenaya Therapeutics, Inc.
-
Patent number: 11926622Abstract: Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.Type: GrantFiled: December 23, 2022Date of Patent: March 12, 2024Assignee: Tenaya Therapeutics, Inc.Inventors: Snahel Patel, Mohammad A. Mandegar, David Sperandio, Julio Medina, Ulhas Bhatt, Alok Nerurkar, Tien Widjaja
-
Patent number: 11913012Abstract: The present disclosure provides methods for generating induced cardiomyocytes and/or inducing a cardiomyocyte phenotype in cells in vivo or in vitro, such as by expression of ASCL1 or MYF6 and MYOCD. The present disclosure further provides gene-delivery vectors comprising one or more polynucleotides selected from ASCL1, MYF6, MYOCD, MEF2C, and TBX5. It further provides compositions comprising induced cardiomyocytes and provides methods of treating a heart condition, such as myocardial infarction. The disclosure also provides engineered myocardin proteins with an internal deletion, vectors encoding such engineered mycocardins, and methods of use thereof.Type: GrantFiled: March 24, 2021Date of Patent: February 27, 2024Assignee: Tenaya Therapeutics, Inc.Inventors: Huanyu Zhou, Laura Lombardi
-
Patent number: 11781156Abstract: Provided herein are methods and compositions for plakophilin-2 gene therapy for treating heart diseases such as arrhythmogenic right ventricular cardiomyopathy (ARVC) or arrhythmogenic cardiomyopathy (ACM).Type: GrantFiled: July 30, 2021Date of Patent: October 10, 2023Assignee: TENAYA THERAPEUTICS, INC.Inventors: Zhihong Jane Yang, Jaclyn Ho, Chris Reid, Jin Yang
-
Patent number: 11759531Abstract: The present disclosure provides methods and compositions useful for the treatment or prevention of heart disease. In particular, the present disclosure provides a vector comprising a modified troponin promoter operatively linked to a therapeutic gene product for the treatment or prevention of heart disease, e.g., cardiomyopathy. The gene product may be MYBPC3. The disclosure also provides recombinant adeno-associated virus (rAAV) virions, rAAV viral genomes, and expression cassettes and pharmaceutical compositions thereof. The disclosure further provides methods for treating a disease or disorder, such as heart disease.Type: GrantFiled: January 21, 2022Date of Patent: September 19, 2023Assignee: Tenaya Therapeutics, Inc.Inventor: Laura Lombardi
-
Publication number: 20230123856Abstract: Provided herein is a compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, Y, X, and n are defined herein. Also provided herein are compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of heart disease.Type: ApplicationFiled: April 4, 2022Publication date: April 20, 2023Applicant: Tenaya Therapeutics, Inc.Inventors: Mohammad A. MANDEGAR, Snahel PATEL, Ulhas BHATT, Pingyu DING, Martin HOLAN, John LEE, Yihong LI, Julio MEDINA, Alok NERURKAR, Frederick SEIDL, David SPERANDIO, Tien WIDJAJA, Xiaodong WANG
-
Patent number: 11578066Abstract: Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.Type: GrantFiled: April 28, 2022Date of Patent: February 14, 2023Assignee: Tenaya Therapeutics, Inc.Inventors: Snahel Patel, Mohammad A. Mandegar, David Sperandio, Julio Medina, Ulhas Bhatt, Alok Nerurkar, Tien Widjaja
-
Patent number: 11446397Abstract: The present disclosure provides methods and compositions useful for the treatment or prevention of heart disease. In particular, the present disclosure provides a vector comprising a modified troponin T promoter operatively linked to a therapeutic gene product for the treatment or prevention of heart disease, e.g., cardiomyopathy. The gene product may be MYBPC3. The disclosure also provides recombinant adeno-associated virus (rAAV) virions, rAAV viral genomes, and expression cassettes and pharmaceutical compositions thereof. The disclosure further provides methods for treating a disease or disorder, such as heart disease.Type: GrantFiled: October 21, 2021Date of Patent: September 20, 2022Assignee: Tenaya Therapeutics, Inc.Inventor: Laura Lombardi
-
Patent number: 11129908Abstract: The present disclosure provides methods and compositions useful for the treatment or prevention of heart disease. In particular, the present disclosure provides a vector comprising a modified troponin T promoter operatively linked to a therapeutic gene product for the treatment or prevention of heart disease, e.g., cardiomyopathy. The gene product may be MYBPC3. The disclosure also provides recombinant adeno-associated virus (rAAV) virions, rAAV viral genomes, and expression cassettes and pharmaceutical compositions thereof. The disclosure further provides methods for treating a disease or disorder, such as heart disease.Type: GrantFiled: March 24, 2021Date of Patent: September 28, 2021Assignee: Tenaya Therapeutics, Inc.Inventor: Laura Lombardi
-
Patent number: 11015211Abstract: The present disclosure provides methods for generating induced cardiomyocytes and/or inducing a cardiomyocyte phenotype in cells in vivo or in vitro, such as by expression of ASCL1 or MYF6 and MYOCD. The present disclosure further provides gene-delivery vectors comprising one or more polynucleotides selected from ASCL1, MYF6, MYOCD, MEF2C, and TBX5. It further provides compositions comprising induced cardiomyocytes and provides methods of treating a heart condition, such as myocardial infarction. The disclosure also provides engineered myocardin proteins with an internal deletion, vectors encoding such engineered mycocardins, and methods of use thereof.Type: GrantFiled: September 22, 2020Date of Patent: May 25, 2021Assignee: Tenaya Therapeutics, Inc.Inventors: Huanyu Zhou, Laura Lombardi